Continuous monitoring device with advanced
features and analytics to deliver personalized insights directly to
the smartphone
Biotricity, Inc.
(NASDAQ:BTCY), a modern medical technology company focused on
delivering innovative, remote biometric monitoring solutions, today
announced the availability of Bioheart, a direct-to-consumer heart
monitor that offers the same continuous heart monitoring technology
used by physicians. Showcased in prototype form at CES 2020,
Bioheart has shipped to preorder customers and is now available for
purchase at www.bioheart.com.
The launch of Bioheart opens a new market and revenue stream for
Biotricity while expanding the company’s total addressable market
by $1.24B, the global heart rate monitoring market. “Launching
Bioheart and expanding into this new market is an important step
for Biotricity and our ultimate goal of building a complete cardiac
ecosystem to service individuals throughout their heart health
journey,” said Dr. Waqaas Al-Siddiq, Founder and CEO of
Biotricity.
Heart conditions are intermittent, requiring long term data
collection for effective insights. With continuous monitoring,
Bioheart reinvents personal heart management with retrospective
snapshots. Introducing a groundbreaking new capability, users can
create snapshots of rhythm data by reviewing past data and marking
it for personal records. This is a first-of-its-kind feature that
will help individuals look back at their data for a richer
understanding of their lifestyle impact and heart health.
Bioheart features include:
With the Bioheart smartphone app, users
can:
- Built-in dry contacts for data collection
- Advanced data collection – three different heart views
- 24/7 continuous rhythm monitoring
- 48 hour battery life
- Personalized analytics
- Bluetooth connected
- View electrical heart rhythm live on the app
- View data on advanced heart metrics such as electrical heart
rhythm, heart rate and heart rate variability
- View historical heart rate ranges
- Create a heart rhythm diary and save snapshots of heart
activity
- Easily create retrospective snapshots, a first-of-its kind
capability
- Easily export and share heart data with a physician
Bioheart incorporates the Company’s proprietary advanced heart
technology, combined with powerful analytics and continuous rhythm
monitoring, to help individuals understand and improve their heart
health. It provides 24/7 electrical heart rhythm monitoring and
recording with three different views of the heart, which can be
streamed live on the Bioheart smartphone app. Bioheart is the most
accurate heart monitor available without a prescription.
“Bioheart combines unparalleled accuracy in a heart monitoring
device with continuous data, advanced heart health insights, and
powerful features tailored to individuals at risk for heart disease
or who want precise data for performance tracking, optimization and
preventative cardiac wellness,” said Dr. Al-Siddiq. “Bioheart
furthers Biotricity’s mission of developing revolutionary
healthcare solutions that help engage and empower individuals to
take control of their health, starting with the deadliest chronic
disease and one of healthcare’s largest cost drivers: cardiac
disease.”
Heart condition signs are typically intermittent, and most heart
monitoring devices only capture short periods of heart activity.
These devices have limited capabilities and do not provide
individuals with the heart data or tools needed to support
preventative care and effective lifestyle improvements. With
Bioheart’s continuous monitoring and long-term data collection
approach, users can analyze heart data from previous months, well
after the initial recording, to understand changes and long-term
trends.
“Bioheart has the potential to make an immediate, life-changing
impact for those who use it,” added Dr. Al-Siddiq. “As a direct
manufacturer, we’re thrilled to have been able to accelerate our
market delivery to the general market in less than a year, ahead of
schedule and in time for the busy holiday gifting season.”
Bioheart retails for $199 and is available for purchase here or
at www.bioheart.com. The app is available on Apple’s App Store and
on Google Play.
You can see Bioheart in action here.
About Biotricity
Biotricity is reforming the healthcare market by bridging the
gap in remote monitoring and chronic care management. Doctors and
patients trust Biotricity’s unparalleled standard for preventive
and personal care, including diagnostic and post-diagnostic
solutions for chronic conditions. The company develops
comprehensive remote health monitoring solutions for the medical
and consumer markets. To learn more, visit www.biotricity.com.
Bioheart name, logo, and tag lines are trademarks of Biotricity
Inc. US and International Patents Pending. Bioheart does not
require a prescription.
Bioheart does not diagnose, treat, or repair heart disease.
Bioheart is not intended to be a diagnostic tool, or for clinical
use, or clinical interpretation, and is meant to be a lifestyle and
wellness solution for individuals. If users of the Bioheart are
concerned about the data obtained from the device, they should
consult a medical professional directly for further advice.
Biotricity disclaims any representation made, whether explicitly or
implicitly, which would suggest the accuracy of the data obtained
is suitable for clinical interpretation.
Bioheart as described herein, and subsequent versions, may or
may not be the same as advertised and may or may not differ in
features and functionality. Any statements made herein in relation
to Bioheart, its features, functionality are based on design and
concepts that the company believe are achievable, but the
functionality may be different.
Important Cautions Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Forward-looking statements, which involve assumptions
and describe our future plans, strategies, and expectations, are
generally identifiable by use of the words “may,” “should,”
“would,” “will,” “could,” “scheduled,” “expect,” “anticipate,”
“estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or
the negative of these words or other variations on these words or
comparable terminology. Forward-looking statements may include,
without limitation, statements regarding (i) the plans, objectives
and goals of management for future operations, including plans,
objectives or goals relating to the design, development and
commercialization of Bioflux, Bioheart, Biokit or any of the
Company’s other proposed products or services, (ii) a projection of
income (including income/loss), earnings (including earnings/loss)
per share, capital expenditures, dividends, capital structure or
other financial items, (iii) the Company's future financial
performance, (iv) the regulatory regime in which the Company
operates or intends to operate and (v) the assumptions underlying
or relating to any statement described in points (i), (ii), (iii)
or (iv) above. Such forward-looking statements are not meant to
predict or guarantee actual results, performance, events or
circumstances and may not be realized because they are based upon
the Company's current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which the
Company has no control over. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Factors that may influence or contribute
to the inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company's inability to obtain
additional financing, the significant length of time and resources
associated with the development of its products and related
insufficient cash flows and resulting illiquidity, the Company's
inability to expand the Company's business, significant government
regulation of medical devices and the healthcare industry, lack of
product diversification, existing or increased competition, results
of arbitration and litigation, stock volatility and illiquidity,
and the Company's failure to implement the Company's business plans
or strategies. These and other factors are identified and described
in more detail in the Company's filings with the SEC. The Company
assumes no obligation to update any forward-looking statements in
order to reflect any event or circumstance that may arise after the
date of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211110005751/en/
Media contacts Bospar prforbiotricity@bospar.com Investor
relations: Biotricity Investor Relations Investors@biotricity.com
1.800.951.3348 Mark Forney MKR Group, Inc. 12198 Ventura Blvd.,
Suite 200 Los Angeles, CA 91604 mark@mkrir.com
Grafico Azioni Biotricity (NASDAQ:BTCY)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Biotricity (NASDAQ:BTCY)
Storico
Da Feb 2024 a Feb 2025
